Wydajno: 50 mg (High Yield Idealny do zaawansowanych formulacji)
Robijn, S., Hoppe, B., Vervaet, B
IGF1R activation via DES(1-3) IGF-1 induced a 2.8-fold increase in S-phase cell population, reversing the 50% S-phase reduction produced by gefitinib monotherapy
Pharmacologic inhibiting STAT3 delays the progression of kidney fibrosis in hyperuricemia-induced chronic kidney disease
Iron loading impairs lipoprotein lipase activity and promotes hypertriglyceridemia
Genome-wide studies have reported interactions with over 4,000 genes, including those associated with tissue remodelling pathways, stem cell regulatory networks, and metabolic gene programmes